Adjuvant treatment of resected nonsmall cell lung cancer: State of the art and new potential developments

Current Opinion in Oncology

Volumn 25, Issue 2, 2013, Pages 115-120

  Felip, Enriqueta ^a   Martinez Marti, Alex ^a   Martinez, Pablo ^a   Cedres, Susana ^a   Navarro, Alejandro ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

adjuvant setting; biomarkers; chemotherapy; NSCLC; targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ATM PROTEIN; BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CANCER VACCINE; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MAGE A3 VACCINE; PLACEBO; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; THYMIDYLATE SYNTHASE; TUBULIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANGIOGENESIS; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESEARCH; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84873727953     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ca1b0     Document Type: Review

References (25)

1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer. N Engl J Med 2004; 350:351-360.
2. Non-Small Cell Lung Cancer Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899-909.
3. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA nonsmall-cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.
4. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with nonsmall cell lung cancer. The surgical setting of the Big Lung Trial. Eur J Cardio Thorac Surg 2004; 26:173-182.
5. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected nonsmall cell lung cancer. N Engl J Med 2005; 352:2589-2597.
6. Douillard JY, Rosell R, Delena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall-cell lung cancer (Adjuvant Navelbine International trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 2006; 7:719-727.
7. Strauss GM, Herndon IIJE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043-5051.
8. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients lace meta-analysis. J Clin Oncol 2008; 26:3552-3559.
9. NSCLC Meta-analyses Collaborative Group; Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable nonsmall-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375:1267-1277.
10. Goss GD, Lorimer I, Tsao MS, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA nonsmall cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010; 28(suppl.; abstr. LBA7005).
11. Tatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
12. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III nonsmall-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-2456.
13. Richardson F, Richardson K, Sennello G, et al. Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). J Clin Oncol 2009; 27:15S(suppl.; abstr. 7520).
14. Neal JW, Pennell NA, Govindan R, et al. The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC). J Clin Oncol 2012; 30:(suppl.; abstr. 7010).
15. Wakelee HA, Dahlberg SE, Keller SM, et al. Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage nonsmall cell lung cancer (NSCLC). J Clin Oncol 2011; 29:(suppl.; abstr. 7013).
16. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multicenter, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II nonsmall cell lung cancer (NSCLC). J Clin Oncol 2007; 25:18S(suppl.; abstr. 7554).
17. Therasse P, Vansteenkiste JF, Zielinski M, et al. MAGRIT phase III trial: MAGEA3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC. J Clin Oncol 2011; 29:(suppl.; abstr. TPS210).
18. Zielinski M, Laskowski U, Bieselt R, et al. Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (antigen-specifi c cancer immunotherapeutic) in adjuvant NSCLC. Eur J Cancer 2009; 7 (Suppl.):511-512.
19. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991.
20. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall-cell lung cancer. J Clin Oncol 2006; 24:4731-4737.
21. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected nonsmall-cell lung cancer. PLoS One 2007; 2:e1129.
22. Gandara DR, Grimminger P, Mack PC, et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in nonsmall cell lung cancer. J Thorac Oncol 2010; 5:1933-1938.
23. Pierceall WE, Olaussen KA, Rousseau V, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012; 23:2245-2252.
24. Shepherd FA, BourredjemA, Brambilla E, et al. Prognostic and predictive effects of KRAS mutation subtype in completely resected nonsmall cell lung cancer (NSCLC): a LACE-bio study. J Clin Oncol 2012; 30(suppl.; abstr. 7007).
25. Sanchez JM, Cobo M, Arrabal R, et al. Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (I) in resected stage II-IIIA nonsmall cell lung cancer (NSCLC) patients (p). J Clin Oncol 2012; 30(suppl.; abstr. 7011).